253-50-9

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Naphthyridine(7CI,8CI,9CI) is used as a drug intermediate for the synthesis of various pharmaceuticals. Its unique structure and properties contribute to the development of new medicines with potential antiviral and antibacterial capabilities.
Used in Agrochemical Industry:
In the agrochemical sector, 2,6-Naphthyridine(7CI,8CI,9CI) serves as a key component in the production of agrochemicals, providing a foundation for the development of effective and innovative solutions for agricultural applications.
Used in Organic Compounds and Materials Production:
2,6-Naphthyridine(7CI,8CI,9CI) is utilized as a building block in the synthesis of various organic compounds and materials, showcasing its versatility and importance in the chemical industry.

InChI:InChI=1/C8H6N2/c1-3-9-6-8-2-4-10-5-7(1)8/h1-6H

Upstream product

• 80935-78-0 1-chloro-[2,6]naphthyridine 
• 222167-62-6 3-(trimethylsilylethynyl)pyridine-4-carboxaldehyde 
• 626-55-1 3-Bromopyridine 
• 70201-43-3 3-bromo-pyridine-4-carbaldehyde 
• 1003-73-2 3-picoline-N-oxide 
• 7584-05-6 3-methyl-4-cyanopyridine 
• 80935-76-8 N,N-dimethylamino-2-(4-cyano-3-pyridyl)ethene 
• 80935-77-9 1,2-dihydro-2,6-naphthyridin-1-one 

Downstream Products

• 80935-81-5 1-amino-2,6-naphtyridine 
• 31786-18-2 1,2,3,4-tetrahydro-2,6-naphthyridine 

Relevant academic research and scientific papers

Cyanido-Bridged FeII–MI Dimetallic Hofmann-Like Spin-Crossover Coordination Polymers Based on 2,6-Naphthyridine

Two new 3D spin-crossover (SCO) Hofmann-type coordination polymers {Fe(2,6-naphthy)[Ag(CN)2][Ag2(CN)3]} (1; 2,6-naphthy = 2,6-naphthyridine) and {Fe(2,6-naphthy)[Au(CN)2]2}·0.5PhNO2 (2) were synthesized and characterized. Both derivatives are made up of infinite stacks of {Fe[Ag(CN)2]2[Ag2(CN)3]}n and {Fe[Au(CN)2]2}n layered grids connected by pillars of 2,6-naphthy ligands coordinated to the axial positions of the FeII centers of alternate layers. The in situ generated [Ag2(CN)3]– linkers define wide rectangular windows that favor the interpenetration of three identical 3D networks, strong argentophilic interactions between them, and the generation of a densely packed structure without accessible void spaces. In contrast, the smaller rhombus-shaped window in 2 affords a structure made up of doubly interpenetrated 3D networks with strong aurophilic interactions between them and accessible voids partially occupied by nitrobenzene molecules. Compound 1 displays a relatively abrupt two-step SCO in the temperature interval 150–215 K, whereas 2 features an incomplete one-step SCO behavior (T1/2 = 166 K) that extends over 150 K.

One-pot homo- and cross-coupling of diazanaphthalenes via C-H substitution: Synthesis of Bis- and Tris-diazanaphthalenes

The transition metal-free coupling reactions of unactivated diazanaphthalenes were studied using only lithium tetramethylpiperidine (LiTMP) reagent. Symmetrical and nonsymmetrical bis-diazanaphthalenes were synthesized in moderate to high yield by homo- and cross-coupling of related monomers. In addition, the single-step synthesis of diquinoxalino [2,3-a: 2', 3'c] phenazine and 2,2': 3', 2″ - terquinoxaline using the appropriate equivalent amount of LiTMP was performed. The products were characterized by means of NMR spectroscopy and HRMS spectrometry.

High-Throughput Screening and Hit Validation of Extracellular-Related Kinase 5 (ERK5) Inhibitors

The extracellular-related kinase 5 (ERK5) is a promising target for cancer therapy. A high-throughput screen was developed for ERK5, based on the IMAP FP progressive binding system, and used to identify hits from a library of 57-617 compounds. Four distinct chemical series were evident within the screening hits. Resynthesis and reassay of the hits demonstrated that one series did not return active compounds, whereas three series returned active hits. Structure-activity studies demonstrated that the 4-benzoylpyrrole-2-carboxamide pharmacophore had excellent potential for further development. The minimum kinase binding pharmacophore was identified, and key examples demonstrated good selectivity for ERK5 over p38α kinase.

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof:wherein Y1 is of formula (?) or formula (y):Ring Y is a 5- to 6-membered heteroaryl ring; and V4, V5, Rx, x, y, and n are as defined herein. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

SUBSTITUTED SULFONAMIDE COMPOUNDS

Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states.

General synthetic method for naphthyridines and their N-oxides containing isoquinolinic nitrogen

Substituted naphthyridines containing isoquinolinic nitrogen were synthesized by the reaction of o-ethynylpyridinecarbaldehydes with ammonia. The synthesis of their N-oxides was also achieved by a basic cyclization reaction of the same pyridine derivatives via the corresponding oximes.

Amination of 2,6- and 2,7-Naphtyridine. An NMR Study on ?-Adducts of Heterocyclic Systems with Amide Ions

A facile synthesis of 2,6-naphtyridine is described.Both 2,6- and 2,7-naphtyridine undergo with potassium amide under kinetically and thermodynamically controlled conditions ?-adduct formation at position 1.Chichibabin amination of 2,6-naphtyridine yields 1-amino-2,6-naphtyridine in 54percent yield.